Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis

BACKGROUND: Treatment requirements of antineutrophil cytoplasmic autoantibody vasculitis (AV) and high comorbidity burden among patients with AV may lead to higher potential for polypharmacy and its associated adverse outcomes, including adverse drug events, nonadherence, drug-drug interactions, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Binxin, Hogan, Susan L, Derebail, Vimal K, Ehlert, Alexa, Thorpe, Carolyn T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387912/
https://www.ncbi.nlm.nih.gov/pubmed/37404075
http://dx.doi.org/10.18553/jmcp.2023.29.7.770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387912/
https://www.ncbi.nlm.nih.gov/pubmed/37404075
http://dx.doi.org/10.18553/jmcp.2023.29.7.770

Ejemplares similares